HLS Therapeutics Partners with Esperion to Bring Cardiovascular Treatments to Canada

HLS Therapeutics Inc ( (TSE:HLS) ) just unveiled an update.

HLS Therapeutics Inc. has partnered with Esperion Therapeutics to commercialize NEXLETOL and NEXLIZET in Canada, targeting a significant unmet medical need for over half a million Canadians with cardiovascular issues. This strategic move aligns with HLS’s business development strategy and strengthens its position in the Canadian cardiovascular market. The agreement involves an upfront payment and potential milestone payments, with HLS funding these through existing cash reserves, indicating no significant increase in operating expenses. This collaboration is expected to enhance HLS’s market presence and provide advanced treatment options for Canadian patients.

Spark’s Take on TSE:HLS Stock

According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.

HLS Therapeutics Inc demonstrates strong operational efficiency and cash management, despite persistent net losses affecting profitability. The stock shows positive momentum above key moving averages, but the lack of profitability and absence of a dividend yield weigh on its valuation. The recent addition to the board is a strategic positive, potentially enhancing the company’s market position.

To see Spark’s full report on TSE:HLS stock, click here.

More about HLS Therapeutics Inc

HLS Therapeutics Inc. is a pharmaceutical company established in 2015, focusing on the acquisition and commercialization of late-stage development and established branded pharmaceutical products in North America. The company targets unmet needs in psychiatric disorders and cardiovascular disease, leveraging a management team with extensive experience in these therapeutic areas.

Average Trading Volume: 10,669

Technical Sentiment Signal: Hold

Current Market Cap: C$138.3M

Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.